Last reviewed · How we verify
FSH-GEX™
At a glance
| Generic name | FSH-GEX™ |
|---|---|
| Also known as | follitropin epsilon |
| Sponsor | Glycotope GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Single Dose FSH-GEX™ in Healthy Volunteers (PHASE1)
- Multiple Dose FSH-GEX(TM) in Healthy Volunteers (PHASE1)
- Efficacy and Safety of FSH-GEX™ in Comparison With 150 IU Gonal-f® (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FSH-GEX™ CI brief — competitive landscape report
- FSH-GEX™ updates RSS · CI watch RSS
- Glycotope GmbH portfolio CI